About US
Contact us
-
Isis receives milestone payment from Biogen Idec for advancement of dystrophy drugUS-based drug developer Isis Pharmaceuticals has obtained a $10m payment from Biogen Idec for the development of a potential treatment for myotonic dystrophy, a chronic, slowly progressing, highly var2013/10/18
-
Novo Nordisk nabs FDA approval for hemophilia fighter NovoEightNovo Nordisk is known for its dominance in the diabetes market. The company sports 5 of the 10 top-selling diabetes remedies worldwide. But the company has a stash of other treatments, and it just add2013/10/17
-
Sanofi invests in Fabrazyme production as sales soarNew plant has allowed Genzyme to overcome shortages of rare-disease drug Sales of Sanofi's rare-disease drugFabrazymehave been on an upward trajectory since it got on top of supply issues last year w2013/10/17
-
Cancer immunotherapies set to storm onto the market, analysts sayOver the past year the excitement in biopharma R&D circles about the therapeutic punch of cancerimmunotherapieshas reached fever pitch, and the intense R&D focus hasn't escaped the notice of t2013/10/16
-
Chinese-produced vaccine prequalified by WHOOn October 9, 2013, the World Health Organization (WHO) notified China Food and Drug Administration that the live attenuated Japanese encephalitis vaccine produced by Chengdu Institute of Biological P2013/10/16
-
Pfizer exec Amy Schulman talks gender, power and company policyIn an interview withThe New York Times, Pfizer SVP and General Counsel Amy Schulman has some advice for ambitious women. Soon to leada new vaccines, oncology and consumer health division at Pfizer ($P2013/10/15
-
Sanofi nabs OTC nod for Nasacort amid consumer healthcare pushSanofi's ($SNY) got a new OTC offering, and consumers will soon have a steroid-based nasal spray option in drugstore aisles. Friday, the FDA backed the sale of allergy medNasacortas anOTC med. It's a2013/10/15
-
How do U.S. drugs come to cost more? Let us count the waysFor a couple of years, GlaxoSmithKline ($GSK) CEOAndrew Wittyhas been assuring investors that the company's big-selling lung drugAdvairwould be tough for generics makers to knock off, even after the d2013/10/14
-
Roche to supersize biologics production to meet biologics' super forecastsSwiss drugmaker to invest nearly $900 million on facilities in U.S., Europe Swiss drugmaker Rochehas seen explosive growth for drugs like its new breast cancer drugKadcylaand says it needs a lot more2013/10/14
-
IPEC Foundation 2013 Award Winners AnnouncedThe IPECFoundation recently announced its 2013 Award Recipients, which will be presented on November 10 in San Antonio, Texas during the American Association of Pharmaceutical Scientists (AAPS) Annual2013/10/12